Arg-Gly-Asp-Cys |
| Catalog No.GC30186 |
Arg-Gly-Asp-Cys는 세포 접착 분자에 대한 피브로넥틴의 결합 모티프이며 혈소판 응집 및 피브리노겐 결합을 억제할 수 있습니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 109292-46-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Arg-Gly-Asp-Cys is the binding motif of fibronectin to cell adhesion molecules, and can inhibit platelet aggregation and fibrinogen binding.
RGDC immobilizes peptide onto DAH-CMTMC is found to be about 15.3 μg/mg of chitosan derivative by amino acid analysis (AAA). RGDC-functionalized chitosan may lead to enhanced wound healing (viability >140%). RGDC-functionalizes chitosan derivatives exhibit in vitro wound healing properties by enhancing fibroblast proliferation and adhesion. RGDC-DAH-CMTMC favors cell growth and an increase in cellular proliferation compared to the control cells[1].
[1]. Patrulea V, et al. Peptide-decorated chitosan derivatives enhance fibroblast adhesion and proliferation in wound healing. Carbohydr Polym. 2016 May 20;142:114-23.
Cell experiment: | Human precursor dermal fibroblasts (HDF, human dermal progenitor cells, 12 week male donor) are use in the assay. WST-1 assay is used to assess the viability of HDF when incubated with chitosan derivatives. For this study, HDF are seeded in a 96-well plate at a density of 6×103 cells/cm2. To each well, 100 μL of cell suspension is added and incubated for 48 h in order to allow cell attachment. DMEM is then replaced by 100 μL of CMTMC and RGDC-DAH-CMTMC suspension at concentrations of 0.25 mg/mL, 0.5 mg/mL and 1 mg/mL, respectively. Cell viability under polymer incubation is evaluated during 2, 4 and 7 days. SDS (1%) is used as negative control. The polymer solution is changed every 3 days. 100 μL of WST-1 (1:10 dilution in DMEM) are added in each well after removing the polymer suspension and incubated for 0.5-2 h. Absorbance is recorded with a BioTek Microplate reader at two different wavelengths (450 and 690 nm). The viability is presented as percentage compared to the positive control group (cells in DMEM supplemented with 10% fetal calf serum). All experiments are carried out in triplicates. |
References: [1]. Patrulea V, et al. Peptide-decorated chitosan derivatives enhance fibroblast adhesion and proliferation in wound healing. Carbohydr Polym. 2016 May 20;142:114-23. | |
| Cas No. | 109292-46-8 | SDF | |
| Canonical SMILES | Arg-Gly-Asp-Cys | ||
| Formula | C15H27N7O7S | M.Wt | 449.48 |
| Solubility | Water : ≥ 50 mg/mL (111.24 mM) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.2248 mL | 11.124 mL | 22.2479 mL |
| 5 mM | 0.445 mL | 2.2248 mL | 4.4496 mL |
| 10 mM | 0.2225 mL | 1.1124 mL | 2.2248 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 24 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *